Efficacy observation of selinexor-based regimen in the treatment of 10 patients with relapsed/refractory
multiple myeloma Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …

Objective Multiple myeloma cells resist standard therapies due to overexpression of the
transport protein, exportin 1. Selinexor is a novel drug that targets the Exportin 1 protein in …

Methods STORM was a phase 2b, open-label study which enrolled pts previously treated
with bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, glucocorticoids …

Introduction Multiple myeloma (MM) is an increasingly treatable but still incurable
hematologic malignancy. Prognosis has improved significantly over recent years, although …

Effectiveness and safety of selinexor-based regimens in the treatment of relapsed and
refractory multiple myeloma: a multicenter real-world study from China Homepage Journals …

Selinexor combined with chemotherapy in relapsed/refractory multiple myeloma: interim results
from the multi-center, open-label LAUNCH study Homepage Journals 1.{{journal.titleEn}} …

Virtually no treatment options are available for patients with multiple myeloma (MM)
refractory to proteasome inhibitors, immunomodulatory agents and monoclonal antibodies …

Introduction: In Multiple Myeloma (MM), nuclear exporter exportin-1 (XPO1) is a target for
selinexor. Selinexor has a promising efficacy and a favorable safety profile in relapsed …

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple
myeloma (MM) have been made. Nevertheless, patients with MM resistant to …

Objective: Unusual setting of medical care Background: Numerous treatment options are
available for patients with multiple myeloma (MM). Because of the course of the disease …